{"id":80406,"date":"2026-05-09T00:06:01","date_gmt":"2026-05-09T00:06:01","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/"},"modified":"2026-05-09T00:06:01","modified_gmt":"2026-05-09T00:06:01","slug":"azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/","title":{"rendered":"Azalea Therapeutics Announces Late-Breaking Oral Presentation at ASGCT Annual Meeting Demonstrating First-in-Primate In Vivo TRAC-CAR T Cell Engineering"},"content":{"rendered":"<div>\n<ul>\n<li style=\"text-align:left;\"><em>First-in-primate data demonstrate in vivo generation of genomic site-specific engineered TRAC-CAR T cells following a single intravenous administration without lymphodepletion<\/em>\n<\/li>\n<li style=\"text-align:left;\"><em>All non-human primates (6 of 6) exhibited deep B cell depletion in peripheral blood by Day 10<\/em>\n<\/li>\n<li style=\"text-align:left;\"><em>Potent B cell clearance observed across peripheral blood, lymph nodes and bone marrow<\/em>\n<\/li>\n<li style=\"text-align:left;\"><em>Treatment was generally well tolerated, with no deaths, no neurotoxicity and no off-target CAR expression or integration detected in non-T cells in the blood<\/em><\/li>\n<\/ul>\n<p>BERKELEY, Calif., May  08, 2026  (GLOBE NEWSWIRE) &#8212; Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines <em>in vivo<\/em>, today announced that first-in-primate data from its proprietary <em>in vivo<\/em> CAR T cell platform have been accepted as a late-breaking abstract for oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, taking place May 11 \u2013 15, 2026 in Boston, Massachusetts.<\/p>\n<p>The late-breaking abstract, titled \u201cA first-in-primate demonstration of <em>in vivo TRAC<\/em>-CAR T cell engineering via cell-selective delivery and genomic locus-specific integration,\u201d describes the first <em>in vivo<\/em> generation of genomic site-specific engineered <em>TRAC<\/em>-CAR T cells in non-human primates. Azalea\u2019s platform is designed to generate CAR T cells directly inside the body through a dual-vector approach that combines CD3-targeted enveloped delivery vehicles (EDVs) delivering transient Cas9 complexes with a T cell-tropic AAV (AAV-T) carrying a promoterless CAR gene flanked by <em>TRAC <\/em>homology arms. This approach enables precise insertion of the CAR gene at the <em>TRAC<\/em> locus, placing CAR expression under control of the endogenous T cell promoter.<\/p>\n<p>In the study, six rhesus macaques received a single intravenous administration of EDV and AAV-T vectors at different dose levels without prior lymphodepletion. The study assessed <em>in vivo TRAC<\/em>-CAR T cell generation, <em>TRAC<\/em>-CAR-mediated B cell depletion in peripheral blood, lymph nodes and bone marrow, and safety parameters.<\/p>\n<p>\u201cThese first-in-primate data represent a major milestone for Azalea and for the broader field of <em>in vivo<\/em> cell engineering,\u201d said Jenny Hamilton, Ph.D., co-founder, president and chief executive officer of Azalea Therapeutics. \u201cIn immune-competent non-human primates, a single intravenous administration of our dual-vector platform generated <em>TRAC<\/em>-CAR T cells <em>in vivo<\/em> and achieved complete target B cell depletion across peripheral blood, lymph nodes and bone marrow without lymphodepletion. We believe that achieving precise insertion at a defined genomic locus will be foundational to the safety, durability and physiologic regulation of future <em>in vivo<\/em> cell therapies. We believe these findings provide important translational support for our approach and the potential to make powerful cell therapies more accessible by eliminating the need for individualized <em>ex vivo <\/em>manufacturing.\u201d<\/p>\n<p><strong>First-in-Primate <\/strong><strong><em>In Vivo TRAC<\/em><\/strong><strong>-CAR T Cell Engineering<\/strong><\/p>\n<p>In the study, animals demonstrated <em>in vivo<\/em> generation of <em>TRAC<\/em>-CAR T cells, with <em>TRAC<\/em>-CAR T cells peaking as high as 41% of all peripheral T cells on Day 11. All six animals demonstrated deep B cell aplasia of greater than 90% in peripheral blood by Day 10.<\/p>\n<p>The study also demonstrated potent target B cell clearance beyond peripheral blood. In lymph nodes and bone marrow, B cells were deeply depleted by greater than 90% in five of six animals at the highest dose level within two weeks following treatment.<\/p>\n<p>Treatment was generally well tolerated, with no deaths, no neurotoxicity and a favorable safety profile. Molecular analyses confirmed no off-target CAR expression or integration in non-T cells in the blood.<\/p>\n<p>\u201cTo our knowledge, this is the first demonstration of site-specific gene integration in T cells in a non-human primate <em>in vivo<\/em>. This study demonstrates that Azalea\u2019s platform can achieve cell-selective delivery, genomic locus-specific CAR insertion and robust pharmacodynamic activity in a clinically relevant non-human primate model,\u201d said Connor Tsuchida, Ph.D., scientific co-founder, vice president of research and development at Azalea Therapeutics and presenting author of the abstract. \u201cThe combination of <em>TRAC<\/em>-targeted integration, endogenous promoter-driven CAR expression and activity across multiple tissue compartments supports continued advancement of this genome editing-based <em>in vivo<\/em> CAR T platform toward clinical translation.\u201d<\/p>\n<p>Azalea will present these data at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q_5HV6WKarHbLAqKbUVbpxXd5EHW6juWLPMjKiW8Exwv4VY3ccC3MJa9oM89_QUr-TCb5ajHHwX9MTtoV-lhCGPSi40Epalr-3EnI1p6wxUixicbzpyfXOJl5vL_5bAw\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>ASGCT 2026 Annual Meeting<\/u><\/a>.<\/p>\n<p><strong>Abstract Title:<\/strong> A first-in-primate demonstration of <em>in vivo TRAC<\/em>-CAR T cell engineering via cell-selective delivery and genomic locus-specific integration<br \/><strong>Presenting Author:<\/strong> Connor A. Tsuchida, Ph.D., Azalea Therapeutics<br \/><strong>Session:<\/strong> Oral Abstract Sessions \u2013 Late-breaking abstracts<br \/><strong>Date\/Time:<\/strong> Friday, May 15, 2026, 8:00 am \u2013 9:45 am ET<br \/><strong>Location:<\/strong> Westin Seaport Commonwealth Ballroom ABC (Concourse Level)<\/p>\n<p><strong>About Azalea Therapeutics<\/strong><br \/>Azalea Therapeutics is a biotechnology company redefining precision genomic medicines <em>in vivo<\/em>. Its proprietary Enveloped Delivery Vehicles (EDV) platform is engineered to deliver transient CRISPR-Cas9 cargo to specific cells in the body for site-specific genome editing with curative intent. Azalea\u2019s first programs leverage T cell-targeting EDVs and highly efficient T cell-tropic AAVs to enable programmable CAR gene insertion at a defined genomic locus, placing expression under control of the cell\u2019s endogenous promoter for physiologic and sustained activity. This approach aims to generate potent, durable and safe therapies directly inside patients, avoiding the complexity of <em>ex vivo<\/em> manufacturing and unlocking new treatment modalities \u2013 including <em>in vivo<\/em> CAR T cell therapies \u2013 across cancer, autoimmune disease and genetic disorders. Azalea is headquartered in Berkeley, California. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IIyvv-gN95WBP34YAILBN2mDq6PJQWJoyQbcLj8ctNnsvSuBa7L9RwDksvje0d99shJBTbwvIXkaIX_nOBX26Q==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>azaleatx.com<\/u><\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VEmBORUfwI7vKA3PtOIBBWhoekqa5nrmXVIP6oCrzbmBBrooliu4GyxW5dh8HkeJwsm4tdhkLkaUydn_bG50MfrXG4_jh0zxfW3zMSGwwUpKMg7cNgG0vboMlTDPLW4J\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>LinkedIn<\/u><\/a>.<\/p>\n<pre>CONTACT: Contact:\r\nNoopur Batsha Liffick, MPH\r\nNBL LifeSci Advisory\r\nnoopur@azaleatx.com<\/pre>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2IzMGRhYWUtYjRhNS00M2NlLTliNGMtMDQxMzFkNmM5MTU1LTEzMTgyNzctMjAyNi0wNS0wOC1lbg==\/tiny\/Azalea-Therapeutics.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>First-in-primate data demonstrate in vivo generation of genomic site-specific engineered TRAC-CAR T cells following a single intravenous administration without lymphodepletion All non-human primates (6 of 6) exhibited deep B cell depletion in peripheral blood by Day 10 Potent B cell clearance observed across peripheral blood, lymph nodes and bone marrow Treatment was generally well tolerated, [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-80406","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Azalea Therapeutics Announces Late-Breaking Oral Presentation at ASGCT Annual Meeting Demonstrating First-in-Primate In Vivo TRAC-CAR T Cell Engineering - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Azalea Therapeutics Announces Late-Breaking Oral Presentation at ASGCT Annual Meeting Demonstrating First-in-Primate In Vivo TRAC-CAR T Cell Engineering\" \/>\n<meta property=\"og:description\" content=\"First-in-primate data demonstrate in vivo generation of genomic site-specific engineered TRAC-CAR T cells following a single intravenous administratio\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-09T00:06:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/04\/sgb-media-kit-2026.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1075\" \/>\n\t<meta property=\"og:image:height\" content=\"716\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Azalea Therapeutics Announces Late-Breaking Oral Presentation at ASGCT Annual Meeting Demonstrating First-in-Primate In Vivo TRAC-CAR T Cell Engineering\",\"datePublished\":\"2026-05-09T00:06:01+00:00\",\"dateModified\":\"2026-05-09T00:06:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/\"},\"wordCount\":847,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/\",\"name\":\"Azalea Therapeutics Announces Late-Breaking Oral Presentation at ASGCT Annual Meeting Demonstrating First-in-Primate In Vivo TRAC-CAR T Cell Engineering - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-05-09T00:06:01+00:00\",\"dateModified\":\"2026-05-09T00:06:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Azalea Therapeutics Announces Late-Breaking Oral Presentation at ASGCT Annual Meeting Demonstrating First-in-Primate In Vivo TRAC-CAR T Cell Engineering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Azalea Therapeutics Announces Late-Breaking Oral Presentation at ASGCT Annual Meeting Demonstrating First-in-Primate In Vivo TRAC-CAR T Cell Engineering - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/","og_locale":"en_US","og_type":"article","og_title":"Azalea Therapeutics Announces Late-Breaking Oral Presentation at ASGCT Annual Meeting Demonstrating First-in-Primate In Vivo TRAC-CAR T Cell Engineering","og_description":"First-in-primate data demonstrate in vivo generation of genomic site-specific engineered TRAC-CAR T cells following a single intravenous administratio","og_url":"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-05-09T00:06:01+00:00","og_image":[{"width":1075,"height":716,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/04\/sgb-media-kit-2026.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Azalea Therapeutics Announces Late-Breaking Oral Presentation at ASGCT Annual Meeting Demonstrating First-in-Primate In Vivo TRAC-CAR T Cell Engineering","datePublished":"2026-05-09T00:06:01+00:00","dateModified":"2026-05-09T00:06:01+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/"},"wordCount":847,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/","url":"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/","name":"Azalea Therapeutics Announces Late-Breaking Oral Presentation at ASGCT Annual Meeting Demonstrating First-in-Primate In Vivo TRAC-CAR T Cell Engineering - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-05-09T00:06:01+00:00","dateModified":"2026-05-09T00:06:01+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/azalea-therapeutics-announces-late-breaking-oral-presentation-at-asgct-annual-meeting-demonstrating-first-in-primate-in-vivo-trac-car-t-cell-engineering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Azalea Therapeutics Announces Late-Breaking Oral Presentation at ASGCT Annual Meeting Demonstrating First-in-Primate In Vivo TRAC-CAR T Cell Engineering"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/80406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=80406"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/80406\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=80406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=80406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=80406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}